Clinical Trial Update: ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of tivantinib (ARQ-197) and erlotinib in locally advanced or metastatic EGFR mutation-positive non-small-cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)
• tivantinib (tivantinib)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: COMPLETED